Redeye provides its initial take on Hansa Biopharma’s Q3 report. Product sales declined sequentially to SEK30m, down from SEK48m in Q2, largely due to fewer transplants during holidays and the pause in the Eurotransplant Program. The US ConfideS study had a positive outcome and Hansa is preparing to submit the BLA to the FDA before this year. Funding improved with the directed issue of USD71m.
LÄS MER
